The glycoprotein CD52 is an important target for clinical antibodies, but its receptor and function have remained a mystery. However, it now seems that CD52 may be released in soluble form by a subpopulation of human T cells and may thereby exert an as-yet-unrecognized regulatory function via the inhibitory molecule Siglec-10.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Bandala-Sanchez, E. et al. Nat. Immunol. 14, 741–748 (2013).
Cao, H. & Crocker, P.R. Immunology 132, 18–26 (2010).
Razi, N. & Varki, A. Glycobiology 9, 1225–1234 (1999).
Crocker, P.R., Paulson, J.C. & Varki, A. Nat. Rev. Immunol. 7, 255–266 (2007).
Chen, G.Y., Tang, J., Zheng, P. & Liu, Y. Science 323, 1722–1725 (2009).
Kivi, E. et al. Blood 114, 5385–5392 (2009).
Coles, A.J. Neurotherapeutics 10, 29–33 (2013).
Rowan, W.C., Hale, G., Tite, J.P. & Brett, S.J. Int. Immunol. 7, 69–77 (1994).
Xia, M.Q. et al. Biochem. J. 293, 633–640 (1993).
Treumann, A., Lifely, M.R., Schneider, P. & Ferguson, M.A. J. Biol. Chem. 270, 6088–6099 (1995).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
M.C. is one of the inventors of alemtuzumab.
Rights and permissions
About this article
Cite this article
Clark, M., Cooke, A. Regulation unmasked by activation. Nat Immunol 14, 696–697 (2013). https://doi.org/10.1038/ni.2646
Published:
Issue Date:
DOI: https://doi.org/10.1038/ni.2646
